文献速递主动脉疾病

用于预测腹主动脉瘤腔内修复术后瘤体缩小的多模态人工智能模型(ART in EVAR研究)

Multimodal Artificial Intelligence Model for Prediction of Abdominal Aortic Aneurysm Shrinkage After Endovascular Repair ( the ART in EVAR study).
PubMed 文献 · J Endovasc Ther · 2025-01-30

该研究方案拟纳入约1000例来自5个血管中心的肾下型腹主动脉瘤患者,回顾性构建多模态人工智能模型以预测腔内修复术后1年瘤体缩小。研究按最大径变化将瘤体分为缩小、稳定、增长及需再干预四组,并联合临床、生物力学与影像数据建模。

要点

  • 术前与术后1年最大径缩小≥5 mm归为瘤体缩小,增长≥5 mm归为增长,变化<5 mm归为稳定。
  • 另设第四组纳入EVAR术后1年内接受腹主动脉瘤相关再干预者。
  • 模型旨在识别早期瘤体缩小机会较低者,以个体化调整EVAR治疗与随访。

核心结论

  • 研究旨在开发稳健且高性能的人工智能模型,预测EVAR术后1年腹主动脉瘤缩小,并可能优化EVAR治疗与随访。

研究设计与样本

  • 回顾性观察性多中心研究,拟从5个有经验的血管中心病历中纳入约1000例患者。
  • 纳入标准为因肾下型腹主动脉瘤行择期EVAR、初始辅助技术成功,且术前与1年随访有相同模态影像(CTA-CTA或超声-超声)。
  • 数据收集包括基线及血管特征、用药、手术数据、术前术后影像、随访数据与并发症。
  • 研究注册号为NCT06250998。

主要发现

  • 术前与术后1年最大径差缩小≥5 mm者为瘤体缩小组,增加≥5 mm者为瘤体增长组,变化<5 mm者为稳定组。
  • 第四组纳入EVAR术后1年内接受腹主动脉瘤相关再干预的所有患者,因并发症与再干预可能影响1年瘤体重塑状态。
  • 术前与术后CTA用于半自动分割与有限元分析,进行解剖与生物力学评估。
  • 所有临床、生物力学与影像数据用于构建瘤体缩小的人工智能预测模型,并用可解释人工智能技术识别描述性最强的输入特征。
  • 人工智能模型得出的预测因素将与常规单变量及多变量逻辑回归分析比较,以寻找预测瘤体缩小的最佳模型。

临床怎么用

  • 作者认为模型可识别早期瘤体缩小机会最初较低者,通过增加术前弹簧圈栓塞、主动瘤囊管理和/或术后氨甲环酸治疗来调整EVAR治疗,这些措施已显示可促进瘤体缩小率但过于复杂和昂贵而无法用于所有患者。
  • 作者认为模型可基于患者个体风险分层EVAR术后监测,并可能减少对40-50%将发生瘤囊缩小患者的随访。
  • 作者预期该人工智能预测模型可改善患者生存并减少EVAR术后再干预次数及相关医疗费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The goal of the study described in this protocol is to build a multimodal artificial intelligence (AI) model to predict abdominal aortic aneurysm (AAA) shrinkage 1 year after endovascular aneurysm repair (EVAR). METHODS: In this retrospective observational multicenter study, approximately 1000 patients will be enrolled from hospital records of 5 experienced vascular centers. Patients will be included if they underwent elective EVAR for infrarenal AAA with initial assisted technical success and had imaging available of the same modality preoperatively and at 1-year follow-up (CTA-CTA or US-US). Data collection will include baseline and vascular characteristics, medication use, procedural data, preoperative and postoperative imaging data, follow-up data, and complications. PROPOSED ANALYSES: The cohort will be stratified into 3 groups of AAA remodeling based on the maximum AAA diameter difference between the preoperative and 1-year postoperative moment. Patients with a diameter reduction of ≥5 mm will be assigned to the AAA shrinkage group, cases with an increase of ≥5 mm will be assigned to the AAA growth group, and patients with a diameter increase or reduction of <5 mm will be assigned to the stable AAA group. Furthermore, an additional fourth group will include all patients who underwent an AAA-related reintervention within the first year after EVAR, because both the complication and the reintervention might have influenced the state of AAA remodeling at 1 year. The preoperative and postoperative CTA scans will be used for anatomical AAA analysis and biomechanical assessment through semi-automatic segmentation and finite element analysis. All collected clinical, biomechanical, and imaging data will be used to create an AI prediction model for AAA shrinkage. Explainable AI techniques will be used to identify the most descriptive input features in the model. Predicting factors resulting from the AI model will be compared with conventional univariate and multivariate logistic regression analyses to find the best model for the prediction of AAA shrinkage. The study is registered at www.clinicaltrials.gov under the registration number NCT06250998. CLINICAL IMPACT: This study aims to develop a robust and high-performance AI model for predicting AAA shrinkage one-year after EVAR, with great potential for optimizing both EVAR treatment and follow-up. The model can identify cases with an initially lower chance of early AAA shrinkage, in whom EVAR-treatment could be tailored by including additional preoperative coil embolization, active sac management and/or postoperative tranexamic acid therapy, which have shown to promote AAA shrinkage rate but are too complex and costly to perform in all patients. The model could aid in stratification of post-EVAR surveillance based on the patient's individual risk and possibly decrease follow-up for the 40-50% of patients who will experience AAA sac shrinkage. Overall, the AI prediction model is expected to improve patient survival and decrease the number of reinterventions after EVAR and associated healthcare costs.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. van Rijswijk RE, Bogdanovic M, Roy J, et al. Multimodal Artificial Intelligence Model for Prediction of Abdominal Aortic Aneurysm Shrinkage After Endovascular Repair ( the ART in EVAR study). J Endovasc Ther. 2025. PMID: 39882767. doi:10.1177/15266028251314359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。